Wafergen Q3 Revenues More than Double | GenomeWeb

NEW YORK (GenomeWeb News) – Wafergen Biosystems today said that revenues in its third quarter more than doubled year over year.

For the three months ended Sept. 30, Wafergen's total revenues reached $389,547, up from $176,608 a year ago as the company took in $125,000 in license and royalty-related revenues in the quarter, compared to none a year ago. Product revenues increased to $264,547 from $176,608.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.